Hepatocyte Growth Factor Signaling and Airspace Maintenance
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 09/2021
End Date: 05/2025
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
- Improve methods for earliest detection and diagnosis and develop effective strategies for preventing the onset and progression of COPD
- Define and characterize the pathogenesis of COPD heterogeneity
- Develop personalized medicine for COPD based on the pathogenesis and clinical heterogeneity
- Promote research that can lead to strategies that help prevent the onset and progression of COPD and improve the quality of COPD care and management
Collaboration: Johns Hopkins University
Activity Type: Research
Activity Description
This NHLBI-funded research activity is being carried out by Johns Hopkins University.COPD/emphysema, the third leading cause of death in the United States, is a chronic inflammatory lung disorder usually triggered by long-term cigarette smoke exposure. Although many therapies reduce the symptoms of COPD, no interventions exist which arrest or reverse the extensive architectural and functional damage that punctuate the disorder. In this study, we examine the mechanisms by which impaired hepatocyte growth factor receptor activity contributes to COPD development and whether enhancing the activity of this receptor and its pathway effects will attenuate acquired lung injury.
Audience
General Audience: Health professionals, Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
This activity was funded through the National Heart, Lung, and Blood Institute.Impact Analysis
Results of program are in progressAdvice or Lessons Learned
In processContact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland